Journal of molecular and cellular cardiology最新文献

{"title":"Prevalence of rare missense TTN variants in a cohort of patients with cardiomyopathy","authors":"Irene Bottillo , Maria Pia Ciccone , Monia Magliozzi , Kalliopi Pilichou , Giorgia Girotto , Francesca Girolami , Massimiliano Cecconi , Valeria D'Argenio , Valeria Novelli , Alessandra Coiana , Daniela Formicola , Emanuele Micaglio , Giada Tortora , Francesca Gualandi , Simona Petrucci , Italian Cardiogenetics Study Group, Marco Castori , Nicoletta Resta , Anna Rita Vestri , Maria Iascone , Paola Grammatico","doi":"10.1016/j.yjmcc.2024.12.004","DOIUrl":"10.1016/j.yjmcc.2024.12.004","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 46-50"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KLF2-dependent transcriptional regulation safeguards the heart against pathological hypertrophy","authors":"Yongqi Wu ,&nbsp;Yujuan Song ,&nbsp;Nan Xie ,&nbsp;Wanqing Zhao ,&nbsp;Jian Lv ,&nbsp;Tingting Zhang ,&nbsp;Yang Zhang ,&nbsp;Hongyin Chen ,&nbsp;Weiyun Sun ,&nbsp;Zhenyu Luo ,&nbsp;Xinhui Cheng ,&nbsp;Tao Jiang ,&nbsp;Zhihua Wang ,&nbsp;Xiaoling Chen ,&nbsp;Yu Hu ,&nbsp;Yu Fang ,&nbsp;Rui Bai ,&nbsp;Xujie Liu ,&nbsp;Xia He ,&nbsp;Zongna Ren ,&nbsp;Li Wang","doi":"10.1016/j.yjmcc.2024.12.010","DOIUrl":"10.1016/j.yjmcc.2024.12.010","url":null,"abstract":"<div><h3>Background</h3><div>Our previous single-cell RNA sequencing study in the adult human heart revealed that cardiomyocytes from both the atrium and ventricle display high activities of Krüppel-like factor 2 (KLF2) regulons. However, the role of the transcription factor KLF2 in cardiomyocyte biology remains largely unexplored.</div></div><div><h3>Methods and results</h3><div>We employed transverse aortic constriction surgery in male C57BL/6 J mice to develop an <em>in vivo</em> model of cardiac hypertrophy, and generated different <em>in vitro</em> cardiac hypertrophy models in neonatal rat ventricular myocytes and human embryonic stem cell-derived cardiomyocytes. Our results demonstrated a significant reduction in KLF2 expression during the progression of cardiac hypertrophy. <em>In vitro</em>, <em>Klf2</em> deficiency exacerbates cardiac hypertrophy and enhances hypertrophic reprogramming, while KLF2 overexpression attenuates cardiac hypertrophy and reverses hypertrophic transcriptome reprogramming. Mechanistically, combined RNA-seq and cleavage under targets &amp; tagmentation (CUT&amp;Tag) analysis revealed that KLF2 exerts its protective effects by directly regulating a set of genes associated with cardiac hypertrophy. <em>In vivo</em>, KLF2 overexpression specifically in cardiomyocytes effectively prevents TAC-induced cardiac hypertrophy in mice. Additionally, we found that simvastatin elevates KLF2 expression in cardiomyocytes, which subsequently alleviates cardiomyocyte hypertrophy.</div></div><div><h3>Conclusions</h3><div>This study provides the first evidence that transcription factor KLF2 serves as a negative regulator of cardiac hypertrophy. Our findings highlight the therapeutic potential of enhancing KLF2 expression, particularly through simvastatin administration, as a promising strategy in the treatment of cardiac hypertrophy.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 62-77"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to commentary from Song et al.","authors":"Satadru K. Lahiri ,&nbsp;Stephan E. Lehnart ,&nbsp;Svetlana Reilly ,&nbsp;Xander H.T. Wehrens","doi":"10.1016/j.yjmcc.2025.01.002","DOIUrl":"10.1016/j.yjmcc.2025.01.002","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 78-79"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2” [Journal of Molecular and Cellular Cardiology. 172(2022) 63–77]","authors":"Jing Fu ,&nbsp;Li Li ,&nbsp;Long Chen ,&nbsp;Congping Su ,&nbsp;Xiuling Feng ,&nbsp;Kai Huang ,&nbsp;Laxi Zhang ,&nbsp;Xiaoyan Yang ,&nbsp;Qin Fu","doi":"10.1016/j.yjmcc.2024.11.003","DOIUrl":"10.1016/j.yjmcc.2024.11.003","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Page 80"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sox17 and Erg synergistically activate endothelial cell fate in reprogramming fibroblasts","authors":"Gregory Farber ,&nbsp;Paige Takasugi ,&nbsp;Shea Ricketts ,&nbsp;Haofei Wang ,&nbsp;Yifang Xie ,&nbsp;Esther Farber ,&nbsp;Jiandong Liu ,&nbsp;Li Qian","doi":"10.1016/j.yjmcc.2024.11.012","DOIUrl":"10.1016/j.yjmcc.2024.11.012","url":null,"abstract":"<div><div><em>Sox17-Erg</em> direct reprogramming is a potent tool for the in vitro and in vivo generation of arterial-like induced-endothelial cells from fibroblasts. In this study, we illustrate the pioneering roles of both <em>Sox17</em> and <em>Erg</em> in the endothelial cell reprogramming process and demonstrate that emergent gene expression only occurs when both factors are co-expressed. Bioinformatic analyses and molecular validation reveal both <em>Bach2</em> and <em>Etv4</em> as integral mediators of <em>Sox17-Erg</em> reprogramming with different roles in lung and heart fibroblast reprogramming. The generated organ-specific induced endothelial cells express molecular signatures similar to vasculature found in the starting cell's organ of origin and the starting chromatin architecture plays a role in the acquisition of this organ-specific identity. Overall, the <em>Sox17-Erg</em> reprogramming mechanism provides foundational knowledge for the future recapitulation of vascular heterogeneity through direct reprogramming.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 33-45"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does coronary microvascular dysfunction play a role in heart failure with reduced ejection fraction?","authors":"Parisa Shabani,&nbsp;Feng Dong,&nbsp;June Yun,&nbsp;Song Yi Shin,&nbsp;Amber Dinchman,&nbsp;Dipan Kundu,&nbsp;Adam Goodwill,&nbsp;James Gadd,&nbsp;Thomas Pucci,&nbsp;Christopher Kolz,&nbsp;Lindsay Shockling,&nbsp;Liya Yin,&nbsp;William Chilian,&nbsp;Vahagn Ohanyan","doi":"10.1016/j.yjmcc.2025.01.007","DOIUrl":"10.1016/j.yjmcc.2025.01.007","url":null,"abstract":"<div><div>Heart failure (HF) is a conundrum in that, current therapies only slow the progression of the disease. We posit, if the causal mechanism were targeted, progression of the disease could be stopped and potentially reversed. We hypothesize that insufficient myocardial blood flow (MBF) produces minute areas of ischemia, that lead to an accumulating injury culminating in HF. Accordingly, we determined the relationship between MBF and cardiac work (wall stress-rate product [WSRP]) in control C57Bl6/J mice (Control), mice with transaortic constriction to produce HF (TAC-HF) and HF mice treated with the coronary vasodilator, chromonar (4 weeks of treatment, TAC-Chromonar). MBF and WSRP were measured during norepinephrine infusion in anesthetized mice. In Controls, MBF increased when work/WSRP was increased with norepinephrine, however, when cardiac work was increased in TAC-HF, MBF did not increase. After chromonar treatment, when work increased, MBF increased. Changes in cardiac function paralleled MBF, i.e., decrement in cardiac function occurred in TAC-HF (ejection fraction), but 4 weeks of chromonar treatment reversed this functional decline. We also found in a model of cardiac hypoxia fate-mapping, a 5-fold increase in the number of hypoxic cardiac myocytes (TAC-HF vs Control), which was reversed by chromonar. Capillary densities also followed this trend with a decrease from Control in TAC-HF, which was restored by Chromonar. We propose that a cause of HF is inadequate MBF to meet the metabolic demands of the working heart. Pharmacological coronary vasodilation with chromonar to increase MBF in HF can reverse the functional decline and improve cardiac function.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"200 ","pages":"Pages 61-67"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SERCA2 dysfunction accelerates angiotensin II-induced aortic aneurysm and atherosclerosis by induction of oxidative stress in aortic smooth muscle cells","authors":"Langtao Wang ,&nbsp;Jiarou Song ,&nbsp;Zhen Yang ,&nbsp;Hailong Zhang ,&nbsp;Yaping Wang ,&nbsp;Jin Liu ,&nbsp;Sai Wang ,&nbsp;Jian Shi ,&nbsp;Xiaoyong Tong","doi":"10.1016/j.yjmcc.2025.01.009","DOIUrl":"10.1016/j.yjmcc.2025.01.009","url":null,"abstract":"<div><h3>Background and aim</h3><div>Our previous research indicates that sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) dysfunction facilitates the phenotypic transformation of aortic smooth muscle cells (ASMCs) and intensifies aortic aneurysm through the regulation of calcium-dependent pathways and endoplasmic reticulum stress. Our hypothesis is that additional mechanisms are involved in aortic aneurysm and atherosclerosis induced by SERCA2 dysfunction from the perspective of ASMC phenotypic transformation.</div></div><div><h3>Methods &amp; results</h3><div>In SERCA2 dysfunctional mice and their control littermates, ASMCs were isolated to analyze protein expression and cell functions, and angiotensin II was infused into these mice that were backcrossed into LDL receptor deficient background to induce aortic aneurysm and atherosclerosis. In ASMCs from SERCA2 dysfunctional mice, the cell cycle was accelerated, and proliferation and migration were enhanced, which could be reversed by SERCA agonist CDN1163 or calcium chelator BAPTA-AM. In ASMCs, SERCA2 dysfunction increased reactive oxygen species (ROS) production, activating extracellular signal-regulated kinases 1 and 2 (ERK1/2) and angiotensin II/angiotensin II type 1 receptor (AT1R) pathways. Both ERK1/2 and angiotensin II/AT1R activations are implicated in SERCA2 dysfunction-induced ASMC phenotypic transformation and ROS production. The redox modulator Tempol suppressed ERK1/2 and angiotensin II/AT1R pathways, inhibiting ASMC phenotypic transformation and alleviating angiotensin II-induced aortic aneurysm and atherosclerosis.</div></div><div><h3>Conclusion</h3><div>SERCA2 dysfunction accelerates aortic aneurysm and atherosclerosis by inducing oxidative stress in ASMCs, with activations of ERK1/2 and angiotensin II/AT1R involved in ASMC phenotypic transformation. Inhibition of oxidative stress in ASMCs is beneficial in alleviating angiotensin II-induced aortic aneurysm and atherosclerosis caused by SERCA2 dysfunction.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"200 ","pages":"Pages 68-81"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circadian influences on sudden cardiac death and cardiac electrophysiology","authors":"Brian P. Delisle ,&nbsp;Abhilash Prabhat ,&nbsp;Don E. Burgess ,&nbsp;Isabel G. Stumpf ,&nbsp;John J. McCarthy ,&nbsp;Spencer B. Procopio ,&nbsp;Xiping Zhang ,&nbsp;Karyn A. Esser ,&nbsp;Elizabeth A. Schroder","doi":"10.1016/j.yjmcc.2025.01.006","DOIUrl":"10.1016/j.yjmcc.2025.01.006","url":null,"abstract":"<div><div>Cardiologists have analyzed daily patterns in the incidence of sudden cardiac death to identify environmental, behavioral, and physiological factors that trigger fatal arrhythmias. Recent studies have indicated an overall increase in sudden cardiac arrest during daytime hours when the frequency of arrhythmogenic triggers is highest. The risk of fatal arrhythmias arises from the interaction between these triggers such as elevated sympathetic signaling, catecholamine levels, heart rate, afterload, and platelet aggregation and the susceptibility of the heart (myocardial substrate) to them. A healthy myocardial substrate has structural and functional properties that protect against arrhythmias. However, individuals with cardiovascular disease often exhibit structural and electrophysiological alterations in the myocardial substrate that predispose them to sustained lethal arrhythmias. This review focuses on how day-night and circadian rhythms, both extrinsic and intrinsic, influence the protective properties of the myocardial substrate. Specifically, it explores recent advances in the temporal regulation of ion channel gene transcription, drawing on data from comprehensive bioinformatics resources (CircaDB, CircaAge, and CircaMET) and recent RNA sequencing studies. We also examine potential mechanisms underlying the temporal regulation of mRNA expression and the challenges in linking rhythmic mRNA expression to corresponding changes in protein levels. As chronobiological research in cardiology progresses, we anticipate the development of novel therapeutic strategies to enhance the protective properties of the myocardial substrate to reduce the risk of fatal arrhythmias and sudden cardiac arrest.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"200 ","pages":"Pages 93-112"},"PeriodicalIF":4.9,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MFN2-mediated decrease in mitochondria-associated endoplasmic reticulum membranes contributes to sunitinib-induced endothelial dysfunction and hypertension","authors":"Yao Qu ,&nbsp;Zhi-Xue Liu ,&nbsp;Xiao-Xu Zheng ,&nbsp;Sheng-Nan Wu ,&nbsp;Jun-Qing An ,&nbsp;Ming-Hui Zou ,&nbsp;Zhi-Ren Zhang","doi":"10.1016/j.yjmcc.2025.01.005","DOIUrl":"10.1016/j.yjmcc.2025.01.005","url":null,"abstract":"<div><div>Treatment of cancer patients with tyrosine kinase inhibitors (TKIs) often results in hypertension, but the underlying mechanism remains unclear. This study aimed to examine the role of mitochondrial morphology and function, particularly mitochondria-associated endoplasmic reticulum membranes (MAMs), in sunitinib-induced hypertension.</div></div><div><h3>Methods</h3><div>Both in vitro and in vivo experiments performed to assesse reactive oxygen species (ROS), nitric oxide (NO), endothelium-dependent vasorelaxation, systemic blood pressure, and mitochondrial function in human umbilical vein endothelial cells (HUVECs) and C57BL/6 mouse aortic endothelial cells, under vehicle or sunitinib treatment condition<em>.</em></div></div><div><h3>Results</h3><div>Sunitinib increased mitochondrial ROS accumulation, decreased oxygen consumption rate, ATP production, and mitochondrial calcium ([Ca²⁺]_M) levels, and impaired endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) signaling in HUVECs. In addition, sunitinib also decreased mitochondrial membrane potential, elongated mitochondria, and reduced MAMs. Remarkably, these effects were reversed by an adeno-virus linker (Ad-linker) that reinforces MAMs. Engineered augmentation of MAMs using AAV-FLT1-linker significantly mitigated sunitinib-induced hypertension, by restoring endothelium-dependent relaxation in mice, highlighting the crucial role of MAMs in this process. Further analyses revealed that sunitinib enhanced Akt-mediated expression of mitofusin 2 (MFN2), causing mitochondrial elongation, and induced dephosphorylation of inositol 1,4,5-trisphosphate receptor type 1 (IP₃R1) at residues Y1737/Y1738, reducing [Ca²⁺]_M. Our study suggests that increased MFN2 expression and IP₃R1 dephosphorylation are critical in sunitinib-induced MAMs reduction and [Ca²⁺]_M homeostasis.</div></div><div><h3>Conclusion</h3><div>Sunitinib induces mitochondrial dysfunction, Akt/MFN2-mediated decrease in MAMs and mitochondrial elongation, and IP₃R1 dephosphorylation in endothelial cells, leading to endothelial dysfunction and hypertension. Our results provide the potential therapeutic targets for combating TKI-induced hypertension.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"200 ","pages":"Pages 45-60"},"PeriodicalIF":4.9,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RyR2 phosphorylation at serine-2814 increases cardiac tolerance to arrhythmogenic Ca2+ alternans in mice","authors":"CA Valverde ,&nbsp;R Agüero ,&nbsp;XHT Wehrens ,&nbsp;M Vila Petroff ,&nbsp;A Mattiazzi ,&nbsp;LA Gonano","doi":"10.1016/j.yjmcc.2025.01.004","DOIUrl":"10.1016/j.yjmcc.2025.01.004","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"200 ","pages":"Pages 40-44"},"PeriodicalIF":4.9,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}